share_log

Alnylam Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Alnylam Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

阿里拉姆制药 | 10-Q：2024财年二季报
美股SEC公告 ·  08/01 05:26

Moomoo AI 已提取核心信息

Alnylam Pharmaceuticals reported robust Q2 2024 financial results, with total revenues of $659.8 million, up 107% year-over-year. Net product revenues reached $410.1 million, driven by strong growth of AMVUTTRA. The company achieved a milestone in its HELIOS-B trial for ATTR amyloidosis with cardiomyopathy, planning global regulatory filings later this year.Research and development expenses increased to $294.1 million, reflecting investments in preclinical activities and clinical trials for zilebesiran and mivelsiran. Selling, general and administrative expenses rose to $248.4 million due to increased marketing efforts for TTR therapies. The company reported a net loss of $16.9 million for the quarter.Alnylam advanced its pipeline with positive results from the KARDIA-2 study of zilebesiran for hypertension and initiated the KARDIA-3 trial. The company also dosed the first patient in the cAPPRicorn-1 Phase 2 trial of mivelsiran for cerebral amyloid angiopathy. With $42.6 million in net cash provided by operating activities, Alnylam believes its current financial position is sufficient to fund operations for at least the next 12 months.
Alnylam Pharmaceuticals reported robust Q2 2024 financial results, with total revenues of $659.8 million, up 107% year-over-year. Net product revenues reached $410.1 million, driven by strong growth of AMVUTTRA. The company achieved a milestone in its HELIOS-B trial for ATTR amyloidosis with cardiomyopathy, planning global regulatory filings later this year.Research and development expenses increased to $294.1 million, reflecting investments in preclinical activities and clinical trials for zilebesiran and mivelsiran. Selling, general and administrative expenses rose to $248.4 million due to increased marketing efforts for TTR therapies. The company reported a net loss of $16.9 million for the quarter.Alnylam advanced its pipeline with positive results from the KARDIA-2 study of zilebesiran for hypertension and initiated the KARDIA-3 trial. The company also dosed the first patient in the cAPPRicorn-1 Phase 2 trial of mivelsiran for cerebral amyloid angiopathy. With $42.6 million in net cash provided by operating activities, Alnylam believes its current financial position is sufficient to fund operations for at least the next 12 months.
阿里拉姆制药发布了2024年第二季度的强劲财务业绩，总收入为65980万美元，同比增长107%。净产品收入达到41010万美元，得益于AMVUTTRA的强劲增长。该公司在其针对伴随心脏病的ATTR淀粉样变的HELIOS-b试验中取得了里程碑，计划在今年晚些时候进行全球监管申请。研究和开发费用增加至29410万美元，反映出在zilebesiran和mivelsiran的临床前活动和临床试验上的投资。由于对TTR疗法的市场推广力度加大，销售、一般和管理费用上升至24840万美元。该公司报告季度净亏损为1690万美元。阿里拉姆在其管线中取得了进展，从KARDIA-2研究中获得了zilebesiran用于高血压的积极结果，并启动了KARDIA-3试验。该公司还为mivelsiran在脑淀粉样血管病的cAPPRicorn-1 II期试验中接种了第一名患者。凭借4260万美元的净现金流，阿里拉姆认为其当前的财务状况足以支持至少接下来12个月的运营。
阿里拉姆制药发布了2024年第二季度的强劲财务业绩，总收入为65980万美元，同比增长107%。净产品收入达到41010万美元，得益于AMVUTTRA的强劲增长。该公司在其针对伴随心脏病的ATTR淀粉样变的HELIOS-b试验中取得了里程碑，计划在今年晚些时候进行全球监管申请。研究和开发费用增加至29410万美元，反映出在zilebesiran和mivelsiran的临床前活动和临床试验上的投资。由于对TTR疗法的市场推广力度加大，销售、一般和管理费用上升至24840万美元。该公司报告季度净亏损为1690万美元。阿里拉姆在其管线中取得了进展，从KARDIA-2研究中获得了zilebesiran用于高血压的积极结果，并启动了KARDIA-3试验。该公司还为mivelsiran在脑淀粉样血管病的cAPPRicorn-1 II期试验中接种了第一名患者。凭借4260万美元的净现金流，阿里拉姆认为其当前的财务状况足以支持至少接下来12个月的运营。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间